Archive for April, 2010

Older Entries
Newer Entries

“Authorized” Generics May Pose Unauthorized Problems

20, Apr 2010

There is a new political football in the war between generic and brand-name drug companies, namely, authorized generics. These are copies of brand-name drugs that are just going off patent, but they are produced by the brand-name company to either hold on to a blockbuster’s market share or to scare off independent generic copies. Which [...]

My Way!

19, Apr 2010

You can almost hear the famous crooner belting out the lyrics about how he “did it his way.” This song always comes to mind when I think about the nearly inexplicable differences in the quality of clinical care across the nation. I am always on the lookout for pithy papers and short summaries that add [...]

Government Moving Slowly on Twig Collection

18, Apr 2010

Of avian influenza hits America, no one will be able to accuse U.S. officials of doing nothing to prepare for the pandemic. This time, there is less likely to be a repeat of the finger-pointing at the Federal Emergency Management Agency (FEMA) and the Bush administration that characterized the post-Hurricane Katrina stories.

European Society of Cardiology: Fish Oil (Omega-3 Polyunsaturated Fatty Acids)

17, Apr 2010

Brouwer IA: Study on Omega-3 Fatty Acids and Ventricular Arrhythmia (SOFA) (Abstract 1336) The SOFA trial examined whether fish oil affected arrhythmias in patients with an implantable cardioverter defibrillator (ICD). The intake of very-long-chain omega-3 polyunsaturated fatty acids (PUFAs), found mainly in fish oil, has been thought to reduce the risk of sudden death, possibly [...]

European Society of Cardiology: Enoxaparin and Unfractionated Heparin

16, Apr 2010

Montalescot G: SafeTy and Efficacy of Intravenous Enoxaparin in Elective Percutaneous Coronary Intervention: An InternationaL Randomized Evaluation (STEEPLE) (Abstract 2574) A bright but still indirect light was thrown on the subject of enoxaparin dosing by a later Hot Line session. The STEEPLE trial compared enoxaparin and UFH in patients undergoing elective PCI. The important difference [...]

European Society of Cardiology

15, Apr 2010

SELECTED SESSIONS Aspirin Serebruany VL: The risk of bleeding complications after different doses of aspirin (ASA): A post-hoc analysis of 192,036patients enrolled in 31 randomized controlled trials (Abstract P3506) A meta-analysis of 31 randomized trials enrolling 192,000 patients was performed to examine the effect of aspirin doses on bleeding. It was found that low daily [...]

American Heart Association: Nesiritide Reduces Mortality Risk in Heart Failure

14, Apr 2010

Speaker: Uri Elkayam, MD, Professor, and Director, Heart Failure Program, Los Angeles County University of Southern California Medical Center, Los Angeles, California Nesiritide (Natrecor, Scios), a recombinant form of human B-type natriuretic peptide (BNP), may diminish the increased acute mortality risk associated with worsening renal function in patients with chronic decompensated heart failure.

Pages: Prev 1 2 3 4 Next

Older Entries
Newer Entries
top